GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Olymvax Biopharmaceuticals Inc (SHSE:688319) » Definitions » Tax Expense

Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Tax Expense : ¥0.4 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chengdu Olymvax Biopharmaceuticals Tax Expense?

Chengdu Olymvax Biopharmaceuticals's tax expense for the months ended in Sep. 2024 was ¥0.0 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2024 was ¥0.4 Mil.


Chengdu Olymvax Biopharmaceuticals Tax Expense Historical Data

The historical data trend for Chengdu Olymvax Biopharmaceuticals's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Olymvax Biopharmaceuticals Tax Expense Chart

Chengdu Olymvax Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only 0.03 - -0.77 17.07 4.18

Chengdu Olymvax Biopharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.98 0.35 - - -

Chengdu Olymvax Biopharmaceuticals Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chengdu Olymvax Biopharmaceuticals  (SHSE:688319) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Chengdu Olymvax Biopharmaceuticals Tax Expense Related Terms

Thank you for viewing the detailed overview of Chengdu Olymvax Biopharmaceuticals's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Chengdu Olymvax Biopharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
99 Tianxin Road, High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
Executives
Li Hong Guang Core technical personnel
Fan Shao Wen Directors, senior managers
Ma Heng Jun senior management
Wu Wei senior management
Fan Fan Director
Chen Ai Min Director
Tan Yong senior management
Lu Lu Director
Yu Yun Hui Director
Chen Dao Yuan Core technical personnel
Zhang Li Ying Core technical personnel
Chen Ke Ping Core technical personnel
Wu Qiang Core technical personnel
Yang Feng Core technical personnel

Chengdu Olymvax Biopharmaceuticals Headlines

No Headlines